Synthesis and Characterization of Novel Hybrid Isoindole Molecules with Thiazole Scaffold

Year 2025, Volume: 14 Issue: 3, 314 - 320, 31.12.2025

Osman Nuri Aslan

https://doi.org/10.54187/jnrs.1780137

Abstract

Thiazole-based compounds exhibit a broad spectrum of bioactivities, including anticancer, antidiabetic, antiviral, antituberculosis, antimalarial, analgesic, anti-inflammatory, antimicrobial, and fungicidal properties. Likewise, isoindole-containing compounds have demonstrated remarkable biological potential, particularly as inhibitors of enzymes such as carbonic anhydrase, HIV (Human Immunodeficiency Virus) protease, cysteine protease, and cyclooxygenase (COX-II), in addition to their antibacterial and antibiotic applications. Given the diverse biological activities of thiazole and isoindole scaffolds, their incorporation into synthetic organic compounds has attracted significant attention from medicinal chemists. In recent years, the design of molecular hybrids has focused on integrating at least two pharmacophoric elements, thereby enabling the simultaneous modulation of multiple disease-related targets. Accordingly, molecular hybridization emerges as a modern strategy for developing multifunctional hybrid molecules by combining distinct pharmacophores within a single structural framework. In this study, hybrid molecules (5a-c and 6a-c), which have potential applications in various therapeutic areas, were effectively synthesized from thiazole derivatives (2a-c) obtained through a series of reactions initiated by acetophenone (1a-c) and carboxylic anhydride (3,4) compounds. The structures of the obtained molecules were detected with spectrometric analysis methods (Fourier Transform Infrared Spectroscopy (FT-IR), Nuclear Magnetic Resonance (NMR-Proton NMR (1H NMR), Carbon NMR (13C NMR), and High-Resolution Mass Spectrometry (HRMS)).

Keywords

Thiazole , isoindole , hybrid molecule , characterization

Ethical Statement

No approval from the Board of Ethics is required.

Supporting Institution

Atatürk Üniversitesi BAP

Project Number

FHD-2025-15935

Thanks

I would like to thank Atatürk University and the Atatürk University BAP Coordination Office for their support. This work was supported by project code FHD-2025-15935.

References

• E. Kalay, Synthesis and characterization of novel hybrid sulfonamide molecules with benzothiazole scaffold, Journal of the Institute of Science and Technology 12 (2) (2022) 899-907.
• F. E. Öztürkkan Özbek, G. Uğurlu, E. Kalay, N. Necefoğlu, Synthesis, characterization and computational studies of 4-[(Pyridine3-carbonyl)-hydrazonomethyl]-benzoic acid, Journal of Molecular Structure 1215 (2020) 128247.
• E. Kalay, I. N. Korkmaz, F. N. Kacı, O. N. Aslan, P. Güller, F. S. Tokalı, R. Kalın, Design, synthesis, and biological studies of isoniazid-based hydrazone derivatives: antibacterial, anticancer, and enzyme inhibitory properties, Archives Biochemistry and Biophysics 770 (2025) 110450.
• R. S. Keri, M. R. Patil, S. A. Patil, S. Budagumpi, A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry, European Journal of Medicinal Chemistry 89 (2015) 207-251.
• Ü. M. Kocyiğit, O. N. Aslan, İ. Gülçin, Y. Temel, M. Ceylan, Synthesis and carbonic anhydrase inhibition of novel 2-(4-(aryl)-thiazole-2-yl)-3a,4,7,7a-tetrahydro-1h-4,7-methanoisoindole-1,3(2h)-dione derivatives, Archiv der Pharmazie – Chemistry in Life Sciences 349 (12) (2016) 955–963.
• G. W. A. Milne, Ashgate handbook of antineoplastic agents, Routledge, 2000.
• J. Das, P. Chen, D. Norris, R. Padmanabha, J. Lin, R. V. Moquin, Z. Shen, L. S. Cook, A. M. Doweyko, S. Pitt, S. Pang, D. R. Shen, Q. Fang, H. F. de Fex, K. W. McIntyre, D. J. Shuster, K. M. Gillooly, K. Behnia, G. L. Schieven, J. Wityak, J. C. Barrish, 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor, Journal of Medicinal Chemistry 49 (23) (2006) 6819-6832.
• M. V. N. De Souza, M. V. De Almeida, Drogas anti-VIH: passado, presente e perspectivas futuras, Quimica Nova 26 (3) (2003) 366-372.
• A. C. Pasqualotto, K. O. Thiele, L. Z. Goldani, Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole, Current Opinion in Investigational Drugs 11(2) (2010) 165-174.
• L. M. Fox, L. D. Saravolatz, Nitazoxanide: a new thiazolide antiparasitic agent, Clinical Infectious Diseases 40 (8) (2005) 1173-1180.
• M. Z. Rehman, C. J. Anwar, S. Ahmad, An efficient synthesis of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides, Bulletin of the Korean Chemical Society 26 (11) (2005) 1771-1775.
• A. A. Nadaf, D. A. Barretto, M. S. Najare, S. Mantur, M. Garbhagudi, S. Gaonkar, S. Joshi, I. A. M. Khazi, Design, Synthesis and biological evaluation of novel N,4-diphenylthiazol-2-amine derivatives, Medicinal Chemistry Research 29 (3) (2020) 442–458.
• C. F. Silva, L. F. Menezes, A. C. Pereira, C. S. Nascimento Jr, Molecularly Imprinted Polymer (MIP) for thiamethoxam: A theoretical and experimental study, Journal of Molecular Structure 1231 (2021) 129980.
• A. W. Mokbel, M. A. Hosny, S. M. Gomha, M. E. A. Zaki, B. Farag, A. F. El Farargy, A. Al Bahir, Y. H. Zaki, Synthesis, molecular docking study, and biological evaluation and of new thiadiazole and thiazole derivatives incorporating isoindoline-1,3-dione moiety as anticancer and antimicrobial agents, Results in Chemistry 7 (2024) 101375.
• V. Ivasiv, C. Albertini, A. E. Gonçalves, M. Rossi, M. L. Bolognesi, Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases, Current Topics in Medicinal Chemistry 19 (19) (2019) 1694-1711.
• V. Abbot, P. Sharma, S. Dhiman, M. N. Noolvi, H. M. Patel, V. Bhardwaj, Small hybrid heteroaromatics: resourceful biological tools in cancer research, RSC Advances 7 (45) (2017) 28313–28349.
• S. Sandhu, Y. Bansal, O. Silakari, G. Bansal, Coumarin hybrids as novel therapeutic agents, Bioorganic & Medicinal Chemistry 22 (15) (2014) 3806–3814.
• N. Kerru, P. Singh, N. Koorbanally, R. Raj, V. Kumar, Recent advances (2015–2016) in anticancer hybrids, European Journal of Medicinal Chemistry 142 (2017) 179–212.
• S. Patil, S. G. Alegaon, S. Gharge, S. D. Ranade, N. A. Khatib, Molecular hybridization, synthesis, in vitro α-glucosidase inhibition, in vivo antidiabetic activity and computational studies of isatin based compounds, Bioorganic Chemistry 153 (2024) 107783.
• O. Özbek, N. C. Usta, M. B. Gürdere, O. N. Aslan, Y. Budak, M. Ceylan, Synthesis and antibacterial screening of novel 2-(4-(aryl) thiazol-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements 192 (10) (2017) 1153-1157.